Cannabis company Cronos Q2 revenue up 21% but misses estimates

Cronos

07/08/2025 12:44

Overview

Cronos Q2 2025 net revenue grows 21% yr/yr, misses analyst expectations

Gross profit rises significantly due to higher sales prices and efficiencies

Co reports net loss of $38.5 mln, impacted by foreign exchange losses

Outlook

Cronos expects accelerated growth in H2 2025

Company anticipates sales boost from Cronos GrowCo expansion in Fall 2025

Company sees positive impact from anti-dumping duty veto in Israel

Result Drivers

INTERNATIONAL DEMAND - Record international and Israel revenue driven by strong global demand for cannabis products

CRONOS GROWCO CONTRIBUTION - Consolidation of Cronos GrowCo added $2.2 mln to Q2 2025 net revenue

ISRAEL MARKET - Record revenue and sales volume in Israel driven by strong demand for high-quality medical cannabis and effective operations, per CEO Mike Gorenstein

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$2.21 mln
$32.90 mln (1 Analyst)
Q2 Net Income
-$38.48 mln
Q2 Adjusted EBITDA
$1.69 mln
Q2 Gross Margin
43.0%
Q2 Capex
$3.84 mln
Q2 Gross Profit
$14.50 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Press Release: ID:nGNX880CYb

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)